| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Apimeds Pharmaceuticals US, Inc (NYSE:APUS) IPO will take place March, 05 on the NYSE exchange under the ticker APUS.
The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on September 01, 2025.
See also: Benzinga IPO Calendar
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that is in the process of developing Apitox, a proprietary intradermally administered bee venom-based toxin, primary focus is to advance Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis ("OA") and, eventually, multiple sclerosis ("MS").
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: APUS
